Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients

OBJECTIVES: A phase I pretargeted radioimmunotherapy trial (EudractCT 200800603096) was designed in patients with metastatic lung cancer expressing carcinoembryonic antigen (CEA) to optimize bispecific antibody and labeled peptide doses, as well as the delay between their injections. METHODS: Three...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Front Med (Lausanne)
Autores principales: Bodet-Milin, Caroline, Ferrer, Ludovic, Rauscher, Aurore, Masson, Damien, Rbah-Vidal, Latifa, Faivre-Chauvet, Alain, Cerato, Evelyne, Rousseau, Caroline, Hureaux, José, Couturier, Olivier, Salaün, Pierre-Yves, Goldenberg, David M., Sharkey, Robert M., Kraeber-Bodéré, Françoise, Barbet, Jacques
Formato: Artigo
Lenguaje:Inglês
Publicado: Frontiers Media S.A. 2015
Materias:
Medicine
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4661432/
https://ncbi.nlm.nih.gov/pubmed/26640780
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmed.2015.00084
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares